

---

# MATTHIAS SCHWAB

---

CV

PARTICIPANT AT:

## EXTREMELY PRETERM BABIES. IMPROVING PERINATAL CARE

January, 16<sup>th</sup>-17<sup>th</sup>, 2013, Barcelona

---



**Matthias Schwab**, Head of the Dept. Clinical Pharmacology, [University Tuebingen and IKP](#), Robert Bosch Hospital, Stuttgart, Germany

Matthias Schwab, MD, PhD., studied medicine at the University Erlangen-Nuernberg, Germany followed by fellowships at the Children's Hospital Nuernberg and the Univ. Hospital Erlangen. A fellowship in Clinical Pharmacology at the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany followed. He received board certifications in Children's Medicine and Clinical Pharmacology. He has held positions at IKP Stuttgart and as visiting professor at St Jude Children's Research Hospital, Memphis, US before he took over the Chair position of Clinical Pharmacology at the University Tuebingen. He is head of the Dept. Clinical Pharmacology, Univ. Tuebingen and IKP, Robert Bosch Hospital, Stuttgart. MS received offers as full professor for Clinical Pharmacology at the University Innsbruck (Austria) and the Karolinska Institute (Sweden). He participates in and/or coordinates a number of national/international research networks and committees (e.g., FP7 ITN, Member of the Executive Committee of EACPT, president of the German Society of Clinical Pharmacology, received numerous awards, and is Editor of Pharmacogenetics & Genomics and Section Editor of Genome Medicine. His scientific accomplishments include more than 250 peer reviewed publications. His scientific interests focus on pharmacogenomics of ADME genes with particularly interest for pediatric subpopulations and the application of novel methodologies (e.g. epigenetics, metabonomics).

B-DEBATE IS AN INITIATIVE OF:

